240 related articles for article (PubMed ID: 31214257)
21. Cost-effectiveness of secukinumab as first biologic treatment, compared with other biologics, for moderate to severe psoriasis in Germany.
Augustin M; McBride D; Gilloteau I; O'Neill C; Neidhardt K; Graham CN
J Eur Acad Dermatol Venereol; 2018 Dec; 32(12):2191-2199. PubMed ID: 29729105
[TBL] [Abstract][Full Text] [Related]
22. No need to change the drug class: ixekizumab- following secukinumab-therapy in psoriasis.
Bokor-Billmann T; Schäkel K
J Dermatolog Treat; 2019 May; 30(3):216-220. PubMed ID: 30051725
[TBL] [Abstract][Full Text] [Related]
23. Twelve-week secukinumab treatment is consistently efficacious for moderate-to-severe psoriasis regardless of prior biologic and non-biologic systemic treatment: Post hoc analysis of six randomised trials.
Hampton P; Halliday A; Aassi M; Subramanian S; Jain M; Griffiths CEM
J Eur Acad Dermatol Venereol; 2021 Apr; 35(4):928-937. PubMed ID: 33030755
[TBL] [Abstract][Full Text] [Related]
24. Cost-effectiveness analysis of secukinumab versus other biologics and apremilast in the treatment of active Psoriatic arthritis: a Finnish perspective.
Purmonen T; Puolakka K; Bhattacharyya D; Jain M; Martikainen J
Cost Eff Resour Alloc; 2018; 16():56. PubMed ID: 30479574
[TBL] [Abstract][Full Text] [Related]
25. Rationale, objectives and design of PURE, a prospective registry of patients with moderate to severe chronic plaque psoriasis in Canada and Latin America.
Papp KA; Gooderham M; Beecker J; Lynde CW; Delorme I; Dei-Cas I; Albrecht L; Rampakakis E; Sampalis JS; Vieira A; Hussein S; Chambenoit O; Rihakova L
BMC Dermatol; 2019 Jun; 19(1):9. PubMed ID: 31226985
[TBL] [Abstract][Full Text] [Related]
26. Secukinumab: A Review in Moderate to Severe Pediatric Plaque Psoriasis.
Blair HA
Paediatr Drugs; 2021 Nov; 23(6):601-608. PubMed ID: 34665445
[TBL] [Abstract][Full Text] [Related]
27. Profile of secukinumab in the treatment of psoriasis: current perspectives.
Roman M; Madkan VK; Chiu MW
Ther Clin Risk Manag; 2015; 11():1767-77. PubMed ID: 26664127
[TBL] [Abstract][Full Text] [Related]
28. Cost-Effectiveness of Secukinumab Versus Other Biologics in the Treatment of Psoriatic Arthritis: An Argentinean Perspective.
Aiello E; Bianculli PM; Bhattacharyya D; Gunda P; Citera G
Value Health Reg Issues; 2019 Dec; 20():86-94. PubMed ID: 31103950
[TBL] [Abstract][Full Text] [Related]
29. Secukinumab-Induced Inflammatory Bowel Disease in a Patient Treated for Chronic Plaque Psoriasis and Psoriatic Arthritis: A Case Report and Review of the Role of Novel Biologic Agents Targeting the p19 Subunit of IL-23.
Darch KM; Holland TL; Spelman LJ
Case Rep Med; 2020; 2020():9404505. PubMed ID: 32774388
[TBL] [Abstract][Full Text] [Related]
30. Drug survival of adalimumab, ustekinumab and secukinumab in patients with psoriasis: a prospective cohort study from the British Association of Dermatologists Biologics and Immunomodulators Register (BADBIR).
Yiu ZZN; Mason KJ; Hampton PJ; Reynolds NJ; Smith CH; Lunt M; Griffiths CEM; Warren RB;
Br J Dermatol; 2020 Aug; 183(2):294-302. PubMed ID: 32124442
[TBL] [Abstract][Full Text] [Related]
31. Narrative Review of the Emerging Therapeutic Role of Brodalumab in Difficult-to-Treat Psoriasis.
Menter A; Bhutani T; Ehst B; Elewski B; Jacobson A
Dermatol Ther (Heidelb); 2022 Jun; 12(6):1289-1302. PubMed ID: 35672564
[TBL] [Abstract][Full Text] [Related]
32. New onset inflammatory bowel disease in patient treated with secukinumab: Case report and review of literature.
Ali AK; Torosian A; Porter C; Bloomfeld RS; Feldman SR
Dermatol Ther; 2021 Nov; 34(6):e15151. PubMed ID: 34609037
[TBL] [Abstract][Full Text] [Related]
33. Cost-effectiveness analysis of sequential biologic therapy with ixekizumab versus secukinumab as first-line treatment of moderate-to-severe psoriasis in the UK.
Johansson EC; Hartz S; Kiri SH; Kumar G; Svedbom A
J Med Econ; 2018 Aug; 21(8):810-820. PubMed ID: 29873270
[TBL] [Abstract][Full Text] [Related]
34. Pustular Psoriasis: A Narrative Review of Recent Developments in Pathophysiology and Therapeutic Options.
Menter A; Van Voorhees AS; Hsu S
Dermatol Ther (Heidelb); 2021 Dec; 11(6):1917-1929. PubMed ID: 34626330
[TBL] [Abstract][Full Text] [Related]
35. Integrating biologic agents into management of moderate-to-severe psoriasis: a consensus of the Canadian Psoriasis Expert Panel. February 27, 2004.
Guenther L; Langley RG; Shear NH; Bissonnette R; Ho V; Lynde C; Murray E; Papp K; Poulin Y; Zip C
J Cutan Med Surg; 2004; 8(5):321-37. PubMed ID: 15868311
[TBL] [Abstract][Full Text] [Related]
36. Biologics for the primary care physician: Review and treatment of psoriasis.
Schadler ED; Ortel B; Mehlis SL
Dis Mon; 2019 Mar; 65(3):51-90. PubMed ID: 30037762
[TBL] [Abstract][Full Text] [Related]
37. Complete response of secukinumab in palmoplantar psoriasis.
Rocamora V; Garcías-Ladaria J
Dermatol Online J; 2017 Oct; 23(10):. PubMed ID: 29469799
[TBL] [Abstract][Full Text] [Related]
38. Scalp psoriasis: report of efficient treatment with secukinumab.
Pistone G; Tilotta G; Gurreri R; Curiale S; Bongiorno MR
J Dermatolog Treat; 2018 Oct; ():1-10. PubMed ID: 30273063
[TBL] [Abstract][Full Text] [Related]
39. A review of secukinumab in psoriasis treatment.
Berg SH; Balogh EA; Ghamrawi RI; Feldman SR
Immunotherapy; 2021 Feb; 13(3):201-216. PubMed ID: 33203276
[TBL] [Abstract][Full Text] [Related]
40. Guselkumab versus secukinumab for the treatment of moderate-to-severe psoriasis (ECLIPSE): results from a phase 3, randomised controlled trial.
Reich K; Armstrong AW; Langley RG; Flavin S; Randazzo B; Li S; Hsu MC; Branigan P; Blauvelt A
Lancet; 2019 Sep; 394(10201):831-839. PubMed ID: 31402114
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
